TDZD-8

TDZD-8

• CAS Number: 327036-89-5
• UNSPSC Description: TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin?B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
• Target Antigen: GSK-3
• Type: Reference compound
• Related Pathways: PI3K/Akt/mTOR;Stem Cell/Wnt
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/TDZD-8.html
• Purity: 99.81
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: O=C(N1CC2=CC=CC=C2)N(C)SC1=O
• Molecular Weight: 222.26
• References & Citations: [1]Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45(6):1292-9.|[2]Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527.|[3]Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76(2):172-83.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported